Biotechnology firm Kodiak Sciences (KOD) saw its stock surge more than 170% on Monday following encouraging data from its AMD trial. Following the completion of the Phase 3 DAYBREAK study in wet age-related macular degeneration (AMD), Kodiak shared notable results that drove the stock up from a previous close in the low $30s to finish the day near $87, before experiencing a minor correction of about 3% the following day.
The company revealed that its two experimental treatments for wet AMD, Zenkuda and KSI-501, successfully achieved their primary endpoint in the late-stage trial. Specifically, Zenkuda showed potential as a new standard-of-care option by providing immediate relief following administration alongside sustained therapeutic effects over the long term.
The upward movement in Kodiak’s shares mirrors the rising valuation momentum seen in tech firms like Advanced Micro Devices (AMD), with both equities advancing on Monday and bringing KOD’s year-to-date gains to 15%. Kodiak estimates the worldwide market for retinal vascular disease medications at $15 billion, positioning itself to secure a foothold in a crowded arena highlighted by Outlook Therapeutics winning approval for its own wet AMD treatment, Lytenava, in late July.
Buoyed by these recent clinical outcomes, Kodiak Sciences intends to submit a Biologics License Application for Zenkuda in the fourth quarter to formally seek marketing authorization from regulators. Should the application succeed, Zenkuda will transition from being a long-standing development pipeline asset into Kodiak’s inaugural commercial product.
At this stage, KOD operates as a high-stakes battleground driven by catalysts. UBS has issued a Buy rating alongside an $80 price target for Kodiak Sciences, asserting that the Phase III wet AMD evaluations for tarcocimab and KSI-501 will likely prove non-inferior to the established benchmark therapy, Eylea. The defining factor lies in the dosing schedule; if Kodiak’s therapies can successfully extend the time between treatments, the commercial outlook transforms from a standard alternative to a significantly more convenient choice, paving the way for premium pricing and robust uptake.